MLN8237 (alisertib), an inhibitor capable of distorting the AURKA conformation, has achieved favourable responses in phase I and phase II clinical trials in combination with irinotecan and temozolomide for the treatment of relapsed or refractory neuroblastoma, which may be a potentially more favourable application of this inhibitor in combination with chemotherapeutic drug therapies.43, 44. The gene discussed is AURKA; the disease is neuroblastoma.